Front. Aging Neurosci. Frontiers in Aging Neuroscience Front. Aging Neurosci. 1663-4365 Frontiers Media S.A. 10.3389/fnagi.2023.1241224 Aging Neuroscience Systematic Review Association of age-related hearing loss with cognitive impairment and dementia: an umbrella review Ying Guo 1 † Zhao Guangran 1 † Xu Xianpeng 2 Su Su 3 * Xie Xin 4 * 1Department of Acupuncture and Moxibustion, The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China 2Department of Otolaryngology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China 3Department of Acupuncture and Moxibustion, Zhuhai Hospital of Integrated of Traditional Chinese Medicine and Western Medicine, Zhuhai, China 4Department of Rehabilitation, Heilongjiang Provincial Hospital, Harbin, China

Edited by: David Gerard Loughrey, Trinity College Dublin, Ireland

Reviewed by: Nattawan Utoomprurkporn, Chulalongkorn University, Thailand; Limkitisupasin Patcharaorn, Chulalongkorn University, Thailand, in collaboration with reviewer NU; David Geldmacher, University of Alabama at Birmingham, United States

 *Correspondence: Su Su, susuazzz8@163.com Xin Xie, 56517254@qq.com

†These authors have contributed equally to this work

 18 09 2023 2023 15 1241224 16 06 2023 30 08 2023 Copyright © 2023 Ying, Zhao, Xu, Su and Xie. 2023 Ying, Zhao, Xu, Su and Xie

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 Background

Hearing loss, cognitive impairment and dementia have become common problems for older adults. Currently, systematic reviews and meta-analyses of the association between age-related hearing loss (ARHL) with cognitive impairment and dementia may have inconsistent results. To explore and validate the association between ARHL with cognitive impairment and dementia through summarizing and evaluating existing evidence.

 Methods

From inception to February 01, 2023, PubMed, Web of Science, Embase, and Cochrane Library databases were systematically searched. AMSTAR 2 was used to evaluate methodological quality and GRADE system was used to evaluate evidence quality. We summarized the basic characteristics of the included studies and extracted effect data for ARHL with cognitive impairment and dementia. Forest plots were used to describe the relative risk associated with ARHL and cognitive impairment, and the relative risk associated with ARHL and dementia, respectively.

 Results

A total of 11 systematic reviews and meta-analyses met the inclusion criteria. Overall, the methodological quality of the included SRs/MAs was moderate and the quality of the evidence was low. The combined results found that the pooled risk ratio of ARHL and cognitive impairment was 1.30 (random-effects; 95% CI 1.16 to 1.45), and the pooled risk ratio of ARHL and dementia was 1.59 (random-effects; 95% CI 1.34 to 1.90).

 Conclusion

Based on the evidence reported in this umbrella review, age-related hearing loss is significantly associated with cognitive impairment and dementia. Hearing loss may be a high risk factor for cognitive impairment and dementia in older adults.

 age-related hearing loss cognitive impairment dementia umbrella review Alzheimer’s disease section-at-acceptance Neurocognitive Aging and Behavior Introduction

Age-related hearing loss (ARHL) is a prevalent complex sensory deficit among older adults, resulting from the cumulative effects of aging on the auditory system (Bowl and Dawson, 2019). The deprivation of hearing in older adults due to ARHL could distance them from regular social activities, potentially leading to social isolation, loneliness, cognitive impairment, and an elevated risk of frailty and falls (Kamil et al., 2016; Rutherford et al., 2018). The count of individuals with hearing loss, previously estimated at 1.57 billion, is projected to surge due to global population aging and demographic shifts (GBD 2019 Hearing Loss Collaborators, 2021). According to the World Health Organization’s World Report on Hearing, approximately 2.5 billion people worldwide could live with varying levels of hearing loss by 2050, with approximately 700 million individuals requiring treatment or rehabilitation services (Chadha et al., 2021). Hearing loss is widespread among older age groups, with those >50 years constituting 62.1% of all hearing loss cases (GBD 2019 Hearing Loss Collaborators, 2021). The risk of ARHL escalates with age, with an estimated prevalence of approximately 40% in the population > 65 years and 50–80% in those >80 years (Gates and Mills, 2005; Davis et al., 2016). Patients experiencing cognitive decline struggle to perceive and process target speech amidst background noise or competing speech, a challenge that might manifest several years before the onset of dementia. Therefore, early identification of hearing loss is pivotal in effectively preventing cognitive impairment and dementia among older adults.

ARHL, ranked the third most formidable chronic disability among older adults, demonstrates its potential relationship with cognitive impairment and dementia (Jafari et al., 2019). Despite evidence indicating ARHL as a possible risk factor for cognitive impairment and dementia, the underlying mechanism remains unclear (Chern and Golub, 2019). As research has deepened, the hypothesis proposing a causal relationship between ARHL and cognitive impairment has gained widespread attention recently. The support for the involvement of neurodegeneration in both ARHL and cognitive impairment comes from research conducted on older adults’ perception and cognition abilities (Fischer et al., 2016). This hypothesis attributes the simultaneous occurrence of ARHL and cognitive impairment to brain atrophy and biological decline (Lalwani et al., 2019). The information-degradation theory states that compromised peripheral auditory function diminishes speech quality due to environmental noise or hearing loss, requiring more “auditory effort” to process acoustic signals. Consequently, limited cognitive resources are diverted from cognitive to hearing tasks, precipitating cognitive decline (Humes et al., 2013). Moreover, the sensory deprivation hypothesis, similar to the information-degradation theory, emphasizes how sensory deprivation prompts compensatory cortical reorganization and neural changes that hinder regular auditory perception and cognitive function (Slade et al., 2020). Although research into the ARHL-cognition relationship is extensive, the absence of robust evidence still clouds the causal relationship between the two, necessitating further clarification of their connection (Livingston et al., 2020).

 Methods

This umbrella review compiles evidence from systematic reviews/meta-analyses (SRs/MAs) concerning multiple clinical questions. It was conducted per a pre-established protocol and adhered strictly to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines (Liberati et al., 2009). The protocol was registered in PROSPERO (registration number CRD42022372393).

Search strategy and selection criteria

Eligible articles were collected through a literature search and screened by two investigators (GRZ, YG) for their title, abstract, and full-text relevance. Databases, including PubMed, Web of Science, Embase, and Cochrane Library, were searched from inception to February 01, 2023. Medical Main Headings (MeSH) terms and keywords encompassed concepts such as “presbycusis” or “age-related hearing loss,” “cognition,” “cognition disorders” or “cognitive dysfunction,” “dementia” or “Alzheimer’s disease,” “meta-analysis” or “systematic review.” Moreover, MeSH and keywords were expanded to include “hearing” or “hearing loss,” and “aged” ensuring comprehensive coverage. References of selected articles were manually reviewed to avoid omitting potentially eligible articles. The definitions of cognitive impairment, dementia, and Alzheimer’s disease are provided in Appendix (p. 2).

This review exclusively incorporated SRs/MAs analyzing the relationship of ARHL with cognitive impairment and dementia. Encompassing cohort, cross-sectional, prospective, and observational studies, the included articles were required to meet specific criteria: (1) The baseline participant population consisted of older adults with community health or cognitive impairment (or dementia) who underwent hearing assessments. Particular groups (such as those with coronary heart disease or hearing-affecting conditions) were excluded; (2) Interventions included peripheral and central hearing loss assessed using diverse methods, including pure tone audiometry, speech audiometry, auditory evoked potentials, self-reported hearing loss, and other primary hearing assessment methods. Cognition was assessed with commonly used tests, such as the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Alzheimer’s Disease Assessment Scale (ADAS), and criteria from the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA). (3) Comparison of cognitive function between patients with and without hearing loss. (4) Outcomes included incidence or prevalence of cognitive impairment or dementia in individuals with hearing loss compared to those with normal hearing and investigations into the potential relationship or risk between hearing loss and cognition. The exclusion criteria were as follows: (1) The title, abstract, and full text of the article were published in a non-English language; (2) Original studies, case reports, conference papers, guidelines, posters, letters, graduate dissertations, or duplicates.

 Methodological and evidence quality evaluation

Methodological and evidence quality evaluations were independently conducted by two investigators (GRZ, YG) using the AMSTAR 2 tool (Shea et al., 2017; A Measurement Tool to Assess Systematic Reviews 2) and the GRADE system (Guyatt et al., 2008; Grading of Recommendations Assessment, Development, and Evaluation), respectively. Any disagreements were resolved through mutual consultation, referencing authoritative guidelines, or consulting a third experienced professor.

The AMSTAR 2 was utilized to assess the methodological quality of the included SRs/MAs and to rate the overall study quality. Comprising 16 evaluation items, each corresponding to a standardization question, the AMSTAR 2 emphasizes the importance of critical things that are pivotal in producing systematic reviews and the validity of results. To prevent masking serious methodological shortcomings due to high overall scores, the AMSTAR 2 R&D team recommends focusing on seven critical items: 2, 4, 7, 9, 11, 13, and 15. Each item was evaluated as “yes,” “partly yes,” or “no” based on the degree of satisfaction. The quality level of system evaluation was categorized as high, moderate, low, and very low based on the results of these evaluations.

The GRADE system pertains to evidence-quality grading and recommendation strength across clinical questions, study design, and outcome indicators. It defines evidence quality and recommendation strength, primarily evaluating the evidence quality grade of system evaluation. This approach surpasses the limitation of considering evidence quality solely from the research design perspective. The GRADE system classifies evidence quality into four levels: high, moderate, low, and very low, aiming for transparency and simplicity. Although the GRADE system automatically downgrades the strength of evidence for observational studies, three criteria that enhance evidence quality are particularly applicable to such analyses. When the effect size of observational studies is substantial, it is feasible to elevate evidence by one or even two notches (Kien et al., 2013). Assessing evidence quality for systematic reviews involves five downgrade factors and three upgrade factors. Downgrade factors encompass risk of bias, inconsistency in results, indirectness of evidence, imprecision, and publication bias. Upgrade factors include a substantial effect, a potential confounder that could alter it, and dose–response gradients.

 Data extraction and statistical analysis

Data extraction was carried out independently by two investigators that fulfilled the inclusion criteria. In instances of disagreement, a third expert mediated and finalized the decisions to ensure consensus. Extracted data encompassed fundamental characteristics of each qualified SRs/MAs, including author, publication year, country, number of studies included, participant count, quality assessment, design, outcomes, main conclusions, effect size with 95% confidence interval (CI), p value, and I2 value.

When available, aggregate effects, CIs, and heterogeneity data from the meta-analysis were extracted for descriptive analysis. We summarized the effect sizes regarding the relationships of hearing loss with cognitive impairment and dementia. Forest plots illustrated these relationships. Statistical analysis was conducted utilizing a random-effects model for the combined study and separately for cross-sectional and cohort studies. Subgroup data analysis was performed with adequate data, using Stata version 17 to generate forest plots.

 Overlap evaluation

Recent years have seen a rise in overlapping studies within systematic reviews, addressing the potential double counting of the same research across two or more reviews. Ignoring or improperly assessing overlapping assessments could notably affect qualitative analysis or statistical weighting. Among numerous methods for evaluating overlap in umbrella overview development, the Graphical Representation of Overlap for Overviews (GROOVE) tool is widely considered the most comprehensive and user-friendly option (Pérez-Bracchiglione et al., 2022). Matrices of evidence and the calculation of corrected covered area (CCA) constitute part of GROOVE’s overlap measurement approach. These matrices visually depict overlap relationships among SRs/MAs, while CCA derives variables from the evidence matrix and computes the overlap rate using a specific formula.

 Results Results of literature search

An initial search across four electronic databases yielded 407 citations related to ARHL, cognitive impairment, and dementia. After removing 54 duplicates, we screened 353 citations by title and abstract, retaining 18 for further assessment. In our umbrella review, subsequent careful full-text screening included 11 sources (Thomson et al., 2017; Wei et al., 2017; Zheng et al., 2017; Ford et al., 2018; Loughrey et al., 2018; Yuan et al., 2018; Utoomprurkporn et al., 2020; Völter et al., 2020; Liang et al., 2021; Kwok et al., 2022; Lau et al., 2022). Figure 1 illustrates the flow chart of literature screening.

Flow diagram of systematic review selection.

 Characteristics of the included studies

The 11 systematic reviews and meta-analyses included in this study were published between 2016 and 2021. Of these, four were from European authors, three from American, three from Chinese, and one from Australian. The quality assessment methods used varied among the included studies: six studies employed the Newcastle-Ottawa Scale (NOS), four did not specify any quality assessment method, and one used the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). The topics covered in the reviews included the correlation between ARHL and cognitive impairment (7 studies), the correlation between ARHL and dementia (4 studies), and the correlation between ARHL and Alzheimer’s disease (3 studies). Further details can be found in Table 1.

Characteristics of the included studies.

Author(s); year Country No. of studies No. of subjects Quality assessment Main conclusions Design/outcomes Relative effect (95% CI) p-value I2
Lau et al. (2022) UK 34 48,017 NOS Significant association between hearing loss and mild cognitive impairment CS/CI RR = 1.44 (1.27, 1.64) <0.0001 0%
Loughrey et al. (2018) Ireland 40 34,471 STROBE Age-related hearing loss may be a biomarker and modifiable risk factor for cognitive decline, cognitive impairment, and dementia CS/CI OR = 2.00 (1.39, 2.89) <0.001 83.1%
CO/CI OR = 1.22 (1.09, 1.36) <0.001 0%
CS/Dementia +AD OR = 2.42 (1.24, 4.72) 0.01 0%
CO/Dementia OR = 1.28 (1.02, 1.59) 0.03 69.7%
CO/AD OR = 1.69 (0.72, 4.00) 0.23 72.6%
Zheng et al. (2017) Chinese 4 7,461 NOS Hearing impairment significantly increased the risk of cognitive impairment and was not significantly different from the risk of Alzheimer’s disease CO/AD RR = 4.87 (0.90, 26.35) 0.066 94.5%
CO/CI + AD RR = 2.82 (1.47, 5.42) 0.002 92.4%
Ford et al. (2018) Australia 14 227,614 / Hearing impairment leads to increased risk of dementia CO/Dementia HR = 1.49 (1.30, 1.67) 0.010 53%
Thomson et al. (2017) America 17 1,378,444 / Hearing loss is associated with a higher incidence of dementia in older adults / / / /
Utoomprurkporn et al. (2020) UK 12 950 / MoCA scores were significantly lower in people with hearing loss than in people with normal hearing NS/CI(MoCA) MD = -1.66 (−2.74, −0.58) 0.003 78%
Völter et al. (2020) Germany 4 425 / Subjects with hearing loss had lower MMSE and MoCA scores than subjects with normal hearing NS/CI(MMSE, MoCA) SD = 0.47 (2.01, 3.86) <0.0005 /
Kwok et al. (2022) America 6 393 NOS The meta-analysis showed that the mean hearing threshold (dB HL) was higher in the AD cohort than in the normal cohort CO/AD(0.5–2 kHz PTA) MD = 2.40 (0.75, 4.05) 0.00044 /
CO/AD(0.5–2 kHz PTA) MD = 3.12 (1.60, 4,64) 0.0001 /
Yuan et al. (2018) Chinese 11 176,893 NOS Older adults have higher levels of hearing loss and a correspondingly higher risk of cognitive impairment CO/CI(follow-up≤6 years) RR = 1.29 (1.04, 1.59) 0.02 0%
CO/CI(follow-up>6 years) RR = 1.57 (1.13, 2.20) 0.008 0%
CO/CI(total) RR = 1.36 (1.14, 1.63) 0.0007 0%
Wei et al. (2017) America 10 15,521 NOS Hearing impairment has been linked to a higher risk of mild cognitive impairment and dementia in older adults CO/CI RR = 1.30 (1.12, 1.51) 0.411 0%
CO/Dementia RR = 2.39 (1.58, 3.61) 0.000 81.4%
Liang et al. (2021) Chinese 14 726,900 NOS Hearing loss may be an independent risk factor for dementia and AD CO/Dementia HR = 1.59 (1.37, 1.86) <0.001 86%
CO/AD HR = 2.24 (1.32, 3.79) 0.003 2%

NOS, Newcastle–Ottawa Scale; STROBE, Strengthening the Reporting of Observational Studies in Epidemiology; MoCA, Montreal Cognitive Assessment; MMSE, Mini-Mental State Examination; PTA, Pure-tone audiogram; CS, Cross-sectional; CO, Cohort; NS, Not Stated; AD, Alzheimer’s Disease; CI, Cognitive Impairment; RR, Relative Risk; OR, Odd Ratio; HR, Hazard Ratio; SD, Standard Difference; MD, Mean Difference.

 Methodological and evidence quality

AMSTAR 2 was employed to assess the methodological quality of the included SRs/MAs. Among the 11 studies, one (9.1%) was rated as high quality, seven (63.6%) as moderate quality, one (9.1%) as low quality, and two (18.2%) as very low quality. Despite their well-developed nature, several studies showed methodological shortcomings, such as incomplete search strategies. However, offering entirely favorable remarks within the search strategy section is challenging due to the absence of gray literature searches, search registration, consultation with field experts, and a renewed search within 24 months after review completion. Another common factor impacting methodology quality was the author’s failure to establish a transparent review methodology in advance and provide an exclusion list and reasons, leading to a reduction in methodological rigor. Analysis revealed that the decision of whether to address publication bias played a pivotal role in the decline of methodological quality, with only two studies examining this factor. Appendix (p. 3) provides more detailed evaluation of AMSTAR 2 projects.

The GRADE system evaluated evidence quality in all included SRs/MAs. Among the 21 evaluation items derived from the 11 reviews, only one (4.8%) was assessed as moderate quality, 11 (52.3%) as low quality, and nine (42.9%) as very low quality. The inherent classification of observational studies as low quality in the GRADE system contributed to the overall low evidence quality. Despite these shortcomings of observational studies, we acknowledge the system’s assessment. Although the overall evidence quality of evidence is not encouraging, only 19 out of 105 downgrade factor evaluations received a “−1,” and six strict upgrade factors received a “1.” Appendix (p. 4) provides a more detailed evaluation of the downgrade factor and upgrade factors of the GRADE system.

 Overlap between included reviews

A total of 55 overlapping associations were identified in the 11 reviews. Among these, 27 nodes had slight overlap, eight had moderate overlap, nine had high overlap, and 11 had very low overlap. A quantitative analysis using CCA indicated an overall CCA of 5.00%, categorizing the overlap as slight. For a comprehensive visual representation, refer to Figure 2, which includes the CCA formula components, calculation, overlapping and non-overlapping primary study counts, and the results presented at each node.

Overlapping of the included reviews.

 Results of systematic reviews Association between ARHL and cognitive impairment

The association between ARHL and cognitive impairment was examined in six reviews (Wei et al., 2017; Loughrey et al., 2018; Yuan et al., 2018; Utoomprurkporn et al., 2020; Völter et al., 2020; Lau et al., 2022), of which four (Wei et al., 2017; Loughrey et al., 2018; Yuan et al., 2018; Lau et al., 2022) were used for the pooled analysis. The combined risk ratio for ARHL and cognitive impairment was 1.30 (random-effects; 95% CI: 1.16–1.45; p = 0.035; I2 = 65.2%). The forest plot (Figure 3) shows the results of the combined meta-analysis for ARHL and cognitive impairment. All the reviews indicated a significant association between ARHL and cognitive impairment. In a study (Loughrey et al., 2018) encompassing both cross-sectional and cohort studies, a substantial association between ARHL and cognitive impairment was identified. This study also revealed significant heterogeneity (Q range, 0.1 to 23.7) and considerable inconsistencies evident in cross-sectional studies, though not in cohort studies. Another meta-analysis (Utoomprurkporn et al., 2020) highlighted worse MoCA scores for individuals with hearing loss, with a pooled mean difference of −1.66 (95% CI: −2.74 to −0.58) from those with normal hearing. Furthermore, a distinct review (Völter et al., 2020) indicated that MoCA and MMSE scores were 2.94 points (SD = 0.47; 95% CI: 2.01–3.86) lower than those with normal hearing, with a significant difference (p < 0.0005).

Forest plot of the association between ARHL and risk of cognitive impairment.

 Association between ARHL with dementia and Alzheimer’s disease

Considering Alzheimer’s disease as a common dementia type, we conducted a pooled meta-analysis of their association. Among six reviews (Wei et al., 2017; Zheng et al., 2017; Ford et al., 2018; Loughrey et al., 2018; Liang et al., 2021; Kwok et al., 2022) reporting the association of ARHL with dementia and Alzheimer’s disease, five contributed to a pooled meta-analysis (Wei et al., 2017; Zheng et al., 2017; Ford et al., 2018; Loughrey et al., 2018; Liang et al., 2021). This analysis revealed a significant association between ARHL and the risk of dementia and Alzheimer’s disease (RR = 1.59; random-effects; 95% CI: 1.34–1.90; p = 0.001; I2 = 73.9%). The forest plot (Figure 4) illustrates the results of the combined meta-analysis for the association of ARHL with dementia and Alzheimer’s disease. One meta-analysis (Loughrey et al., 2018) reported a significant ARHL–dementia association in cross-sectional and cohort studies; however, no significant association was identified with Alzheimer’s disease. Another meta-analysis (Zheng et al., 2017) showed a relative risk of 4.87 (95% CI: 0.90–26.35; p = 0.066) for Alzheimer’s disease in patients with hearing impairment; however, it was insignificant. A more recent meta-analysis (Liang et al., 2021) of prospective cohort studies identified a higher risk of Alzheimer’s disease associated with hearing loss (HR = 2.24; 95% CI: 1.32–3.79; p = 0.003).

Forest plot of the association between ARHL and risk of dementia.

 Discussion

This comprehensive umbrella review synthesized existing systematic reviews and meta-analyses, assessed their methodological quality and evidence strength, and conducted a pooled meta-analysis of relevant data. With the methodological quality of the studies included in this umbrella review being moderate and the evidence quality being low, the results of the pooled meta-analysis still suggested a strong association of ARHL with cognitive impairment and dementia. Therefore, a thorough examination and understanding of this association holds positive implications for diagnosing and preventing hearing-related health issues and neurodegeneration in the older adult population and is critical for public health decision-making in related domains. Within the older adult demographic presenting hearing abnormalities within the realm of audiology, routine cognitive assessments could aid in the early identification of neurodegeneration. Likewise, individuals with mild cognitive impairment could greatly benefit from timely audiological evaluations. Early identification of risk factors, risk reduction strategies, pathophysiological features, and interventions during the pre-clinical phase of the disease carry substantial advantages for patients, society, and public health at large (Crous-Bou et al., 2017).

Although the precise mechanism underlying the association between hearing impairment and cognitive decline remains unclear, this study does not address the question. However, it is noteworthy that we incorporated a meta-analysis (Yuan et al., 2018) demonstrating that older adults with peripheral and central hearing loss face elevated risks of cognitive impairment compared to those with normal hearing. Moreover, ARHL stemming from cochlear hair cell loss, resulting in reduced auditory cortex, and ARHL due to specific deficits in auditory information processing by the central auditory nerve are associated with cognitive deficits. This association is because aging could lead to hair cell loss and deficits in auditory information processing (Gates et al., 2011; Panza et al., 2018). “Information-degradation” and “common-cause” hypotheses offer credible explanations. The “information-degradation” hypothesis proposes that cognitive decline in older adults results from compensatory mechanisms due to impaired auditory input processing. The cognitive resources are diverted to compensate for sensory impairment, ultimately contributing to cognitive decline (Tun et al., 2009). This hypothesis explains the independent impact of sensory and perceptual impairment on cognitive decline. The “common-cause” hypothesis proposes that a shared mechanism underlies age-related changes in cognition, hearing, and other senses due to widespread neurodegeneration. Both hearing loss and cognitive impairment are considered outcomes of neurodegenerative processes prevalent in the aging brain (Schubert et al., 2017). Hearing loss and neuropathology-induced cognitive impairment co-occur in this hypothesis, explaining the sensory impairments frequently accompanying cognitive decline. No single theory comprehensively explains all the intricacies, indicating that multiple mechanisms could coexist.

The Lancet Society for Prevention, Intervention, and Care has introduced a novel lifetime-based dementia risk model where hearing loss is the most substantial modifiable risk factor among the 12 health and lifestyle factors associated with dementia (Livingston et al., 2020). Utilizing diverse strategies to provide timely and effective medical interventions related to hearing and cognition for individuals with ARHL and cognitive impairment could potentially thwart and slow the onset of dementia while enhancing patients’ quality of life. Hearing aids represent the primary avenue for hearing rehabilitation and enhancing auditory communication capabilities for patients with ARHL (Dawes et al., 2015). Hearing-amplification technological aid could reduce hearing impairment and tinnitus while improving cognitive function, social interaction, and quality of life for individuals with ARHL (Manchaiah et al., 2017). In cases of severe hearing loss, hearing aids might not effectively amplify sound, particularly in higher frequency ranges, possibly leading to partial patient neglect of their condition, contributing to heightened cognitive impairment and dementia. Profound hearing loss necessitates the implementation of a cochlear implant, which converts and integrates external sound signals for transmission to the cochlear nerve (Naples and Ruckenstein, 2020). Despite their benefits in addressing ARHL and cognitive impairment, hearing aids and cochlear implants have limitations. Hearing aids are less effective for severe hearing loss and noisy environments, and cochlear implants are associated with progressive residual hearing loss, expense, and limited availability.

Several limitations exist within our study. Primarily, the GRADE evaluation system, commonly used for assessing evidence quality grades, initially categorized observational studies as low quality, which might impact our studies’ evidence quality grade and recommendation strength. Secondly, inconsistencies in the systematic evaluation of intervention and outcome indicators, and statistical approaches hindered the inclusion of all variables in our analysis, possibly introducing publication bias.

 Conclusion

In conclusion, this comprehensive umbrella review underscores the significant association of ARHL with cognitive impairment and dementia. Hearing loss could pose a substantial risk for cognitive impairment and dementia among older adults. Future intervention studies must validate the effectiveness of earing amplification techniques or related therapies in alleviating ARHL-induced cognitive impairment. Moreover, exploring the causal relationship between ARHL and cognitive impairment remains crucial for devising future accurate diagnosis, prevention, and treatment strategies.

 Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.

 Author contributions

GZ and GY presented this review question and study design, responsible for writing the manuscript, performed the literature screening, data extraction, and quality assessment. XPX screened the potential literature. XX and SS proofread the extracted data. SS participated in the review of the manuscript. All authors contributed to the article and approved the submitted version.

 Funding

This work was supported by Heilongjiang Education Department Young Innovative Talents Training Program (no. UNPYSCT-2020231) and Heilongjiang Province Postdoctoral Research Fund (no. LBH-Q21182).

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnagi.2023.1241224/full#supplementary-material

 References Bowl M. R. Dawson S. J. (2019). Age-related hearing loss. Cold Spring Harb. Perspect. Med. 9:a033217. doi: 10.1101/cshperspect.a033217, PMID: 30291149 Chadha S. Kamenov K. Cieza A. (2021). The world report on hearing, 2021. Bull. World Health Organ. 99, 242–242A. doi: 10.2471/BLT.21.285643, PMID: 33953438 Chern A. Golub J. S. (2019). Age-related hearing loss and dementia. Alzheimer Dis. Assoc. Disord. 33, 285–290. doi: 10.1097/WAD.0000000000000325, PMID: 31335455 Crous-Bou M. Minguillón C. Gramunt N. Molinuevo J. L. (2017). Alzheimer's disease prevention: from risk factors to early intervention. Alzheimers Res. Ther. 9:71. doi: 10.1186/s13195-017-0297-z, PMID: 28899416 Davis A. McMahon C. M. Pichora-Fuller K. M. Russ S. Lin F. Olusanya B. O. . (2016). Aging and hearing health: the life-course approach. Gerontologist 56, S256–S267. doi: 10.1093/geront/gnw033, PMID: 26994265 Dawes P. Emsley R. Cruickshanks K. J. Moore D. R. Fortnum H. Edmondson-Jones M. . (2015). Hearing loss and cognition: the role of hearing AIDS, social isolation and depression. PLoS One 10:e0119616. doi: 10.1371/journal.pone.0119616, PMID: 25760329 Fischer M. E. Cruickshanks K. J. Schubert C. R. Pinto A. A. Carlsson C. M. Klein B. E. K. . (2016). Age-related sensory impairments and risk of cognitive impairment. J. Am. Geriatr. Soc. 64, 1981–1987. doi: 10.1111/jgs.14308, PMID: 27611845 Ford A. H. Hankey G. J. Yeap B. B. Golledge J. Flicker L. Almeida O. P. (2018). Hearing loss and the risk of dementia in later life. Maturitas 112, 1–11. doi: 10.1016/j.maturitas.2018.03.004, PMID: 29704910 Gates G. A. Anderson M. L. McCurry S. M. Feeney M. P. Larson E. B. (2011). Central auditory dysfunction as a harbinger of Alzheimer dementia. Arch. Otolaryngol. Head Neck Surg. 137, 390–395. doi: 10.1001/archoto.2011.28, PMID: 21502479 Gates G. A. Mills J. H. (2005). Presbycusis. Lancet 366, 1111–1120. doi: 10.1016/S0140-6736(05)67423-5 GBD 2019 Hearing Loss Collaborators (2021). Hearing loss prevalence and years lived with disability, 1990-2019: findings from the global burden of disease study 2019. Lancet 397, 996–1009. doi: 10.1016/S0140-6736(21)00516-X Guyatt G. H. Oxman A. D. Kunz R. Vist G. E. Falck-Ytter Y. Schünemann H. J. (2008). What is "quality of evidence" and why is it important to clinicians? BMJ 336, 995–998. doi: 10.1136/bmj.39490.551019.BE Humes L. E. Busey T. A. Craig J. Kewley-Port D. (2013). Are age-related changes in cognitive function driven by age-related changes in sensory processing? Atten. Percept. Psychophys. 75, 508–524. doi: 10.3758/s13414-012-0406-9, PMID: 23254452 Ioannidis J. (2017). Next-generation systematic reviews: prospective meta-analysis, individual-level data, networks and umbrella reviews. Br. J. Sports Med. 51, 1456–1458. doi: 10.1136/bjsports-2017-097621 Jafari Z. Kolb B. E. Mohajerani M. H. (2019). Age-related hearing loss and tinnitus, dementia risk, and auditory amplification outcomes. Ageing Res. Rev. 56:100963. doi: 10.1016/j.arr.2019.100963, PMID: 31557539 Kamil R. J. Betz J. Powers B. B. Pratt S. Kritchevsky S. Ayonayon H. N. . (2016). Association of hearing impairment with incident frailty and falls in older adults. J. Aging Health 28, 644–660. doi: 10.1177/0898264315608730, PMID: 26438083 Kien C. Gartlehner G. Kaminski-Hartenthaler A. Meerpohl J. J. Flamm M. Langer G. . (2013). GRADE-Leitlinien: 9. Heraufstufen der Qualität der Evidenz [GRADE guidelines: 9. Rating up the quality of evidence]. Z. Evid. Fortbild. Qual. Gesundhwes. 107, 249–255. doi: 10.1016/j.zefq.2013.04.007, PMID: 23790707 Kwok S. S. Nguyen X. T. Wu D. D. Mudar R. A. Llano D. A. (2022). Pure tone audiometry and hearing loss in Alzheimer's disease: a meta-analysis. Front. Psychol. 12:788045. doi: 10.3389/fpsyg.2021.788045, PMID: 35153910 Lalwani P. Gagnon H. Cassady K. Simmonite M. Peltier S. Seidler R. D. . (2019). Neural distinctiveness declines with age in auditory cortex and is associated with auditory GABA levels. NeuroImage 201:116033. doi: 10.1016/j.neuroimage.2019.116033, PMID: 31326572 Lau K. Dimitriadis P. A. Mitchell C. Martyn-St-James M. Hind D. Ray J. (2022). Age-related hearing loss and mild cognitive impairment: a meta-analysis and systematic review of population-based studies. J. Laryngol. Otol. 136, 103–118. doi: 10.1017/S0022215121004114, PMID: 34895373 Liang Z. Li A. Xu Y. Qian X. Gao X. (2021). Hearing loss and dementia: a meta-analysis of prospective cohort studies. Front. Aging Neurosci. 13:695117. doi: 10.3389/fnagi.2021.695117, PMID: 34305572 Liberati A. Altman D. G. Tetzlaff J. Mulrow C. Gotzsche P. C. Ioannidis J. P. A. . (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700. doi: 10.1136/bmj.b2700 Livingston G. Huntley J. Sommerlad A. Ames D. Ballard C. Banerjee S. . (2020). Dementia prevention, intervention, and care: 2020 report of the lancet commission. Lancet 396, 413–446. doi: 10.1016/S0140-6736(20)30367-6, PMID: 32738937 Loughrey D. G. Kelly M. E. Kelley G. A. Brennan S. Lawlor B. A. (2018). Association of age-related hearing loss with cognitive function, cognitive impairment, and dementia: a systematic review and meta-analysis. JAMA Otolaryngol. Head Neck Surg. 144, 115–126. doi: 10.1001/jamaoto.2017.2513, PMID: 29222544 Manchaiah V. Taylor B. Dockens A. L. Tran N. R. Lane K. Castle M. . (2017). Applications of direct-to-consumer hearing devices for adults with hearing loss: a review. Clin. Interv. Aging 12, 859–871. doi: 10.2147/CIA.S135390, PMID: 28553093 Naples J. G. Ruckenstein M. J. (2020). Cochlear implant. Otolaryngol. Clin. N. Am. 53, 87–102. doi: 10.1016/j.otc.2019.09.004 Panza F. Lozupone M. Sardone R. Battista P. Piccininni M. Dibello V. . (2018). Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life. Ther. Adv. Chronic. Dis. 10:204062231881100. doi: 10.1177/2040622318811000 Pérez-Bracchiglione J. Meza N. Bangdiwala S. I. Niño de Guzmán E. Urrútia G. Bonfill X. . (2022). Graphical representation of overlap for OVErviews: GROOVE tool. Res. Synth. Methods 13, 381–388. doi: 10.1002/jrsm.1557 Rutherford B. R. Brewster K. Golub J. S. Kim A. H. Roose S. P. (2018). Sensation and psychiatry: linking age-related hearing loss to late-life depression and cognitive decline. Am. J. Psychiatry 175, 215–224. doi: 10.1176/appi.ajp.2017.17040423, PMID: 29202654 Schubert C. R. Cruickshanks K. J. Fischer M. E. Chen Y. Klein B. E. K. Klein R. . (2017). Sensory impairments and cognitive function in middle-aged adults. J. Gerontol. A Biol. Sci. Med. Sci. 72, 1087–1090. doi: 10.1093/gerona/glx067, PMID: 28535277 Shea B. J. Reeves B. C. Wells G. Thuku M. Hamel C. Moran J. . (2017). AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 358:j4008. doi: 10.1136/bmj.j4008, PMID: 28935701 Slade K. Plack C. J. Nuttall H. E. (2020). The effects of age-related hearing loss on the brain and cognitive function. Trends Neurosci. 43, 810–821. doi: 10.1016/j.tins.2020.07.005 Thomson R. S. Auduong P. Miller A. T. Gurgel R. K. (2017). Hearing loss as a risk factor for dementia: a systematic review. Laryngoscope Investig. Otolaryngol. 2, 69–79. doi: 10.1002/lio2.65, PMID: 28894825 Tun P. A. McCoy S. Wingfield A. (2009). Aging, hearing acuity, and the attentional costs of effortful listening. Psychol. Aging 24, 761–766. doi: 10.1037/a0014802, PMID: 19739934 Utoomprurkporn N. Woodall K. Stott J. Costafreda S. G. Bamiou D. E. (2020). Hearing-impaired population performance and the effect of hearing interventions on Montreal cognitive assessment (MoCA): systematic review and meta-analysis. Int. J. Geriatr. Psychiatry 35, 962–971. doi: 10.1002/gps.5354, PMID: 32458435 Völter C. Götze L. Dazert S. Wirth R. Thomas J. P. (2020). Impact of hearing loss on geriatric assessment. Clin. Interv. Aging 15, 2453–2467. doi: 10.2147/CIA.S281627, PMID: 33408469 Wei J. Hu Y. Zhang L. Hao Q. Yang R. Lu H. . (2017). Hearing impairment, mild cognitive impairment, and dementia: a meta-analysis of cohort studies. Dement. Geriatr. Cogn. Dis. Extra. 7, 440–452. doi: 10.1159/000485178, PMID: 29430246 Yuan J. Sun Y. Sang S. Pham J. H. Kong W. J. (2018). The risk of cognitive impairment associated with hearing function in older adults: a pooled analysis of data from eleven studies. Sci. Rep. 8:2137. doi: 10.1038/s41598-018-20496-w, PMID: 29391476 Zheng Y. Fan S. Liao W. Fang W. Xiao S. Liu J. (2017). Hearing impairment and risk of Alzheimer's disease: a meta-analysis of prospective cohort studies. Neurol. Sci. 38, 233–239. doi: 10.1007/s10072-016-2779-3, PMID: 27896493